Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-21-001954
Filing Date
2021-05-13
Accepted
2021-05-13 16:01:24
Documents
35
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cns_10q-033121.htm 10-Q 233283
2 CERTIFICATION cns_ex3101.htm EX-31.1 6869
3 CERTIFICATION cns_ex3102.htm EX-31.2 6915
4 CERTIFICATION cns_ex3201.htm EX-32.1 3188
5 CERTIFICATION cns_ex3202.htm EX-32.2 3376
  Complete submission text file 0001683168-21-001954.txt   1710030

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE cnsp-20210331.xml EX-101.INS 217011
7 XBRL SCHEMA FILE cnsp-20210331.xsd EX-101.SCH 21639
8 XBRL CALCULATION FILE cnsp-20210331_cal.xml EX-101.CAL 25197
9 XBRL DEFINITION FILE cnsp-20210331_def.xml EX-101.DEF 99018
10 XBRL LABEL FILE cnsp-20210331_lab.xml EX-101.LAB 178511
11 XBRL PRESENTATION FILE cnsp-20210331_pre.xml EX-101.PRE 144545
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 21919469
SIC: 2834 Pharmaceutical Preparations